Intimation of Scheme of Arrangement, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) Strides is pleased to announce that the Hon''ble National Company Law Tribunal (NCLT), Mumbai Bench has pronounced Order on November 14, 2024 (which was uploaded on NCLT website on November 19, 2024) sanctioning the Scheme of Arrangement for creation of Onesource, India''s first specialty pharma CDMO. (As Per BSE Announcement Dated on 19.11.2024) Intimation of Record Date under Regulation 42 of SEBI Listing Regulations (As Per BSE Announcement dated on 26.11.2024) Intimation of Effective Date for the Scheme of Arrangement amongst Strides, Steriscience and OneSource and their respective shareholders (As Per BSE Announcement dated on 27.11.2024) Trading Members of the Exchange are hereby informed that, pursuant to the Scheme of Arrangement as approved by the Hon'ble National Company Law Tribunal, Mumbai Bench, STRIDES PHARMA SCIENCE LIMITED, has fixed Record Date for the purpose of Demerger and for determining the entitlement of the shareholders of the Company, as per details given below: - COMPANY NAME CODE STRIDES PHARMA SCIENCE LIMITED (532531) RECORD DATE 06.12.2024 PURPOSE As per Scheme of Arrangement (Demerger) approved by the Hon'ble National Company Law Tribunal, Mumbai Bench, between, STRIDES PHARMA SCIENCE LIMITED (the Demerged Company) and OneSource Specialty Pharma Ltd. (the Resulting Company) and their Respective Shareholders and Creditors; The Scheme provides for Demerger of identified CDMO Business and Soft Gelatin Business of STRIDES PHARMA SCIENCE LIMITED, (Demerged Company) INTO OneSource Specialty Pharma Ltd. (Resulting Company) ; As consideration for the Demerger, OneSource Specialty Pharma Ltd, shall issue and allot Equity Shares to the shareholders of STRIDES PHARMA SCIENCE LIMITED in the following proportion:- 1 (One) Equity Share of Re. 1/- each fully Paid-Up of OneSource Specialty Pharma Ltd to be issued and alloted for every 2 (Two) Equity Shares of Rs. 10/- each fully Paid-Up held by the shareholder in STRIDES PHARMA SCIENCE LIMITED EX-ENTITLEMENT FROM DATE & SETT. NO. 06/12/2024 DR-772/2024-2025 Note: (1) Pursuant to SEBI Circular No. SEBI/Cir/ISD/1/2010 dated November 2, 2010, Trading members are hereby informed that the Trading in the Equity Shares of the aforesaid Company shall be transferred from A' Group to T' group w.e.f. 6th December, 2024, and (2) Pursuant to SEBI Circular No. CIR/MRD/DP/01/2012 dated January 20, 2012, the aforesaid scrip shall be a part of Call Auction in Pre-open Session (Special Pre- open Session (SPOS)) on 6th December, 2024. For further information on SPOS, the trading members are requested to refer to the Exchanges notice no. 20120216-29 dated February 16, 2012 on Enabling Special Pre-open Session. Subject to compliance with requisite formalities, the Equity Shares of the Resulting Company i.e. OneSource Specialty Pharma Ltd. will be listed on BSE Limited. (As Per BSE Notice Dated on 29.11.2024) Newspaper Advertisement - Notice of Record Date (As per BSE Announcement Dated on 30/11/2024) Allotment of Equity Shares by Onesource Specialty Pharma Limited pursuant to Scheme of Arrangement. Apportionment of Cost of Acquisition of Equity Shares pursuant to the Scheme. (As per BSE Announcement Dated on 11/12/2024) Submission of report of the Audit Committee and the Independent directors of the Company pursuant to Para D of Part-I of SEBI Master Circular number SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20,2023. (As Per Bse Announcement Dated on 11.04.2025)